ScreenEC: Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

CYTOMARK, a non-invasive in vitro diagnostic (IVD) test measuring a defined panel of protein biomarkers in cervical fluid, can accurately detect endometrial cancer in both symptomatic and asymptomatic women at high risk for the disease. The aim of the study consists in validating CYTOMARK's ELISA test, creating and freezing an algorithm detect EC in post-menopausal women with abnormal uterine bleeding (AUB).

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 40
Healthy Volunteers: t
View:

• 1 - Post-menopausal women (≥1 year without menstruation) with AUB who present with: Endometrium \> 3mm by transvaginal ultrasound, OR

⁃ Endometrium ≤ 3mm who meet at least one of the following criteria:

⁃ Persistent symptoms (more than one episode of metrorrhagia) Heterogenous endometrium on transvaginal ultrasonography Risk factors (BMI ≥ 30, use of tamoxifen, hormone replacement therapy (HRT), Lynch syndrome, BRCA mutation.

⁃ \- 2 - Obtaining written informed consent

Locations
Other Locations
Spain
Hospital Universitari Campus Vall d'Hebron
RECRUITING
Barcelona
Hospital Universitari de Bellvitge
RECRUITING
L'hospitalet De Llobregat
Contact Information
Primary
Antonio Gil-Moreno, MD, PhD
antonio.gil@vallhebron.cat
934893066
Backup
Eva Colás, PhD
eva.colas@mimark.es
934893066
Time Frame
Start Date: 2024-06-24
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 3000
Treatments
Consultancy participants
Eligible participants are postmenopausal women presenting with abnormal uterine bleeding (AUB) in a clinical consultation or primary care setting, for whom a cytology procedure is performed. Cervical samples must be obtainable directly during the consultation at clinical centers with prior Ethics Committee approval. Only participants who meet all inclusion criteria and none of the exclusion criteria will be enrolled
Related Therapeutic Areas
Sponsors
Collaborators: Hospital Vall d'Hebron
Leads: MiMARK Diagnostics, S.L.

This content was sourced from clinicaltrials.gov